![Ishita Chatterjee](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ishita Chatterjee
Profile
Ishita Chatterjee is the founder of Oligomerix, Inc. which was founded in 2006.
She also worked as a Senior Scientist at ARMGO Pharma, Inc.
Former positions of Ishita Chatterjee
Companies | Position | End |
---|---|---|
Oligomerix, Inc.
![]() Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Founder | - |
ARMGO Pharma, Inc.
![]() ARMGO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
ARMGO Pharma, Inc.
![]() ARMGO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY. | Health Technology |
Oligomerix, Inc.
![]() Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Retail Trade |
- Stock Market
- Insiders
- Ishita Chatterjee